

# LEUKOCARE

## Leukocare appoints Professor Ulrike Protzer as member to the Scientific Advisory Board

**Martinsried/Munich, Germany, Feb 15, 2021**

Leukocare AG, a biotechnology company specialized in the field of biopharmaceutical formulation development, today announced the appointment of Professor Ulrike Protzer, professor for Virology at the Technical University of Munich and at Helmholtz Zentrum Muenchen, as additional member to the company's Scientific Advisory Board (SAB). The SAB works closely with the scientific management team to help grow the technology strategy portfolio of Leukocare and to advice on current and future research activities.

Dr Andreas Seidl, Chief Operating Officer at Leukocare, commented, "I am delighted to welcome Professor Protzer to our SAB. Ulrike is a distinguished leader in the field of virology and thus the perfect choice to complement our SAB. In light of the ongoing COVID-19 pandemic, our team is working on several vaccine development projects. Therefore, Ulrike's vast knowledge of understanding the interaction between viruses and their hosts and translating this knowledge into novel therapies and vaccines, will be highly useful for our team and projects. I am very much looking forward to work with Ulrike. "

Leukocare's SAB comprises of Professor Johannes Buchner, Ph.D., Technical University of Munich, Germany, Professor Paul Dalby, Ph.D., University College London, United Kingdom, Professor Theodore Randolph, University of Colorado, Boulder, USA, and Professor Ulrike Protzer, Ph.D., Technical University of Munich, Germany.

Prof. Ulrike Protzer studied medicine in Germany, South Africa and Switzerland. She is an expert clinical virologist with clinical training in infectious diseases and hepatology before she focused on virology. Her scientific efforts focus on understanding the interaction between viruses and their hosts and on translating this knowledge into novel therapies and vaccines. Since 2007, she is a professor for Virology at the Technical University of Munich and at Helmholtz Zentrum Muenchen. She is leading three national and international research consortia, was member of the executive board of the German Center for Infection Research and now is the speaker of its Thematic Translational Unit "Viral Hepatitis". She has published more than 145 peer-reviewed papers and 30 review articles and holds several international patents.

## **About Leukocare AG**

Leukocare AG, located in Martinsried/Munich, Germany, is a biotechnology company specialized in the field of biopharmaceutical formulation development. Operating at the interface of drug substance and drug product development, Leukocare combines sound knowledge of formulation development with bioinformatics and artificial intelligence.

The formulation development approach consists of two elements: a library of up to 100 different regulatory well-established and employed excipients and a rational development approach which employs statistical software and self-learning algorithms as well as state of the art design of experiment (DoE) matrices. By utilizing the artificial intelligence elements, Leukocare is able to specifically combine excipients leading to stabilizing formulations tailored to the drug product's needs.

Leukocare's superior and innovative drug product formulations can be applied to a broad range of applications: biologics & biosimilars, vaccines & viral vectors and biofunctionalized devices.

[www.leukocare.com](http://www.leukocare.com)

### **Contact:**

Dr. Andreas Seidl

COO

[andreas.seidl@leukocare.com](mailto:andreas.seidl@leukocare.com)

+49 (0) 89 7801 6650

Rebekka Ströver

Specialist Communications & Marketing

[rebekka.stroeever@leukocare.com](mailto:rebekka.stroeever@leukocare.com)

+ 49 (0) 89 7801 665 14